Clazakizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | IL6 |
Clinical data | |
Legal status |
|
Routes of administration |
infusion |
Identifiers | |
CAS Number | 1236278-28-6 |
ATC code | none |
Chemical data | |
Formula | C6426H9972N1724O2032S42 |
Molecular mass | 145.2 kDa |
Clazakizumab (formerly ALD518 and BMS-945429)[1] is an aglycosylated, humanized monoclonal antibody against interleukin-6.[2] It is an investigational drug for cancer and rheumatoid arthritis due to its anti-inflammatory properties.
The relatively long half-life of about 30 days should allow less frequent and subcutaneous injections.[3]
It is made using yeast cells rather than the standard Chinese hamster ovary cells.[3]
Contents
Clinical trials
Cancer
A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.[4]
A phase II trial for advanced cancer is due to end in Oct 2009.[5] Results due June 2010.[6] Results from 124 non-small cell lung cancer (NSCLC) patients were favourable (e.g. 1/10 the weight loss).[2]
It may be trialled in a dual therapy with Tarceva owing to a likely synergy.[7] Lua error in package.lua at line 80: module 'strict' not found.
Rheumatoid arthritis
The Phase IIa trial for rheumatoid arthritis[8] has completed with promising results leading to a licensing deal allowing phase III trials.[9] The results are to be presented in June 2010 at the European League Against Rheumatism (EULAR) meeting in Rome.[10] [11] Results showed that ALD518 in addition to MTX performs markedly better than MTX + placebo with a maximum ACR score, (ACR70, i.e. >70% of joints improved), after 16 weeks .[12]
2011: A phase 2 trial reported good results in patients not responsive to methotrexate (MTX).[13]
Oct 2013 : A phase 2B clinical trial has met its primary endpoint (ACR20 response at 12 weeks).[1] Adalimumab with MTX was included as a comparison in the trial.[1]
2014 : A dose ranging phase 2B trial was running.[14]
Crohn's disease
A phase II trial for Crohn's disease initially due to run until 2015.[15] has been prematurely discontinued after having recruited 71 patients out of 288.[16]
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
References
- ↑ 1.0 1.1 1.2 Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology
- ↑ 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 3.0 3.1 http://www.xconomy.com/seattle/2008/09/18/alder-sets-stage-for-showdown-with-roche-with-fast-follower-antibody-drug-strategy/
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://www.boliven.com/clinical_trial/NCT00866970 Phase II: "Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia"
- ↑ http://www.xconomy.com/seattle/2010/05/13/alder-seeks-to-treat-cancer-patients-in-a-radical-way-fighting-inflammation-not-tumors/?single_page=true
- ↑ http://www.nature.com/scibx/journal/v3/n35/full/scibx.2010.1056.html Inflaming resistance to Tarceva. 2010
- ↑ http://clinicaltrials.gov/ct2/show/NCT00867516 Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis (ALD518-003)
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://www.xconomy.com/seattle/2010/03/19/innovation-northwest-wrapup-alder-tekmira-acucela-other-emerging-little-biotechs/ March 2010
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://www.clinicaltrials.gov/ct2/show/study/NCT01545050?show_locs=Y
Further reading
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Bristol-Myers Squibb
- Antibodies
- Anti-inflammatory agents
- Anti-IL-6